Romanian patients’ access to innovative medicines is still far too limited and difficult compared to other EU Member States. In Europe, patients can wait between four months and two and a half years for access to the same new medicines depending on the country, with Romania being at the bottom of this ranking. www.CaleaEuropeana.ro brings you the latest developments at European level on patient access to innovative medicines, but especially the situation of Romanian patients, who, according to statistics, are among the EU citizens who have access to the fewest new treatments and who wait the longest for their approval on the market.
Expert reports have shown that Romania urgently needs to prioritise access for Romanian patients to innovative medicines on the European market, so that they do not have to wait more than 700 days longer than a German patient for a new treatment.
According to the EFPIA PATIENT W.A.I.T. 2020 indicator (published in 2021), North-Western European countries have access to the latest generation of medicines much faster than their neighbours in Southern and Eastern Europe, with patients in some countries waiting more than seven times longer, according to new research. Access is fastest in Germany, with an average of 120 days between marketing authorisation and availability in the country, while Romania ranks last, with an average of 883 days.
By 1 January 2021, 13 treatments for rare diseases will be available in Romania, out of a total of 47 adopted by the European Medicines Agency between 2016 and 2019. Thus, our country has access to only 29% of all orphan drugs, below the European average of 41%.

- Out of 152 innovative medicines approved by the European Medicines Agency between 2016 and 2019, only 39 (1 out of 4) have been included on the list of compensated and free medicines in Romania by 1 January 2021.

- For the 39 medicines that Romanian patients can access for free, they wait on average 883 days, days), up from the previous report, while other Europeans have access immediately or within a few months (Germany 120 days, Italy 418, Bulgaria 692).

The effects of poor access to innovative treatments
The report “Healthcare outcomes and expenditure in Central and Eastern Europe – a review”, published by EFPIA, shows that delayed access leads to lower life expectancy. If we look at the example of Romania, we see that life expectancy is 75 years compared to the average of the five most developed European countries, which is 82 years. To catch up with the current pace of access to care and innovation, it will take Romania 27 years to reach the same average life expectancy as the 5 most developed European countries.
It will also take Romania between 40 and 50 years at the current rate to reduce preventable mortality and mortality from cardiovascular and cerebrovascular diseases to the level of the indicators of the five most developed European countries.
Delayed access to state-of-the-art drugs means days of life lost: a lower survival rate for Romanian prostate and breast cancer patients compared to the average of the 5 most developed European countries and 40,000 years of life lost due to disability in Romania in 2016.
The main reasons for the delays are
- Waiting time to submit the reimbursement file (waiting for other countries to decide on reimbursement). The bureaucratic process of publication of the List of reimbursed medicines and therapeutic protocols: only price approval and obtaining the HTA opinion together take on average 10-12 months.
- A Health Technology Assessment (HTA) system that does not provide mechanisms for assessing the degree of innovation
- An undersized team that is struggling to cope with the dossiers submitted by pharmaceutical companies.
- Lack of budgetary forecasts to ensure the necessary funding for regular and predictable updates of the Reimbursement List.
- Lack of a patient pathway with clear timelines and late diagnosis (especially for oncology and rare diseases).
Also, according to the CRA report, “Report on root causes of market access delays“, there are 10 interrelated factors that explain the lack of medicines in local markets and access delays.
For Romania, the 3 main factors negatively influencing access are
- Failure to meet deadlines for assessment and lack of predictability in updating the list of compensated medicines.
- Lack of multi-annual budget projections and insufficient budget for innovative medicines.
- Dysfunctions related to the procurement process of medicines in hospitals.
All these inequalities among patients in the European Union are intended to be tackled by new strategies and programmes at European level. To this end, the European Commission has launched the Pharmaceutical Strategy for Europe, which is an ambitious project aimed at strengthening the patient focus of the European pharmaceutical system and making it resilient to future health crises. It was adopted last November as a pillar of the European Health Union.
On 28 September 2021, the European Commission published a new public consultation on the review of EU pharmaceutical legislation. The consultation will run until 21 December and will gather views from both the general public and stakeholders.
Efforts are being made at European level to identify the fastest possible access solutions for patients, but a continuous dialogue at national level between authorities and industry is needed to reap the benefits of these European projects.
COVID-19 has also brought new paradigms in terms of approval, regulation and access to medicines. This experience represents new opportunities for the further implementation of health policies that respond to the needs of society and patients.
Ensuring patient access to state-of-the-art treatments should be a common goal and responsibility. Regulators, health system partners, patients, governments and industry need to work together to find new ways to fund these innovative treatments and to ensure patient access and sustainability of health systems at national level.





